Integra LifeSciences
IART
221 hedge funds and large institutions have $3.42B invested in Integra LifeSciences in 2017 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 80 increasing their positions, 80 reducing their positions, and 25 closing their positions.
32% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 25
4% more funds holding
Funds holding: 213 → 221 (+8)
2.24% more ownership
Funds ownership: 88.72% → 90.96% (+2.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 80
2% less capital invested
Capital invested by funds: $3.5B → $3.42B (-$79.2M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $43K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$174M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$30.6M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$18.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$17.8M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$32.4M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$21.1M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$19.8M |
| 4 |
O
OrbiMed
New York
|
-$18.6M |
| 5 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
-$15.7M |
IART Hedge Fund Activity: Q4 2017 in Review
221 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q4 2017, worth a combined $3.42B — down 2.3% from $3.5B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new IART positions and 25 closed out — a net gain of 8 holders — while 80 added to existing stakes and 80 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $174M. The largest seller was Fidelity Investments, cutting an estimated $32.4M.
- 221 institutional investors held Integra LifeSciences (IART) as of Q4 2017, up from 213 in Q3 2017.
- Funds reported $3.42B of Integra LifeSciences stock for Q4 2017, down 2.3% quarter-over-quarter.
- 33 funds opened new Integra LifeSciences positions in Q4 2017 and 25 closed out, a net change of +8 holders.
- The largest Integra LifeSciences buyer in Q4 2017 was Capital Research Global Investors, an estimated $174M added.
- The largest Integra LifeSciences seller in Q4 2017 was Fidelity Investments, an estimated $32.4M sold.
Based on aggregated 13F filings for Q4 2017.